CORONA,Statins,and Heart Failure: Who Lost the Crown?

Tsouli SG , Liberopoulos EN , Goudevenos JA , et al. Should a statin be prescribed to every patient with heart failure? [published online ahead of print August 12, 2007]. Heart Fail Rev. PMID:17694432.

Shanes JG , Minadeo KN , Moret A. , et al. Statin therapy in heart failure: prognostic effects and potential mechanisms. Am Heart J. 2007;154:617-623.

Tousoulis D. , Charakida M. , Stefanadi E. , et al. Statins in heart failure. Beyond the lipid-lowering effect. Int J Cardiol. 2007 ;115:144-150.

Kjekshus J. , Apetrei E. , Barrios V. , et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med. 2007;357:2248-2261.

Go AS , Lee WY , Yang J. , et al. Statin therapy and risks for death and hospitalization in chronic heart failure JAMA. 2006;296:2105-2111.

Foody JM , Shah R. , Galusha D. , et al. Statins and mortality among elderly patients hospitalized with heart failure. Circulation. 2006;113:1086-1092.

LaRosa JC , Grundy SM , Waters DD , et al. Treating to New Targets (TNT) Investigators: intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425-1435.

Khush KK , Waters DD , Bittner V. , et al. Effect of high-dose atorvastatin on hospitalizations for heart failure. Subgroup analysis of the Treating to New Targets (TNT) study. Circulation. 2007;115:576-583.

Athyros VG , Papageorgiou AA , Mercouris BR , et al. Treatment with atorvastatin to the National Cholesterol Educational Program goal versus “usual” care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study Curr Med Res Opin. 2002;18:220-228.

FDA. Lipitor®. (Atorvastatin Calcium) Tablets . http://www.fda.gov/medwatch/safety/2007/Sep_PI/Lipitor_PI.pdf. Accessed December 29, 2007.

Kjekshus J. , Pedersen TR , Olsson AG , et al. The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. J Card Fail. 1997; 3:249-254.

de Lemos JA , Blazing MA , Wiviott SD , et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA. 2004;292:1307-1316.

The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339: 1349-1357.

Sola S. , Mir MQ , Lerakis S. , et al. Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure. J Am Coll Cardiol. 2006;47:332-337.

van der Harst P. , Voors AA , van Gilst WH Statins and autonomic function in chronic heart failure. Cardiovasc Drugs Ther. 2005 ;19:167-168.

Bonaduce D. , Petretta M. , Marciano F. , et al. Independent and incremental prognostic value of heart rate variability in patients with chronic heart failure Am Heart J. 1999;138: 273-284.

Pehlivanidis AN , Athyros VG , Demitriadis DS , et al. Heart rate variability after long-term treatment with atorvastatin in hypercholesterolaemic patients with or without coronary artery disease Atherosclerosis. 2001 ;157:463-469.

Hanna IR , Heeke B. , Bush H. , et al. Lipid-lowering drug use is associated with reduced prevalence of atrial fibrillation in patients with left ventricular systolic dysfunction . Heart Rhythm. 2006;3:881-886.

Ganotakis ES , Mikhailidis DP , Vardas PE Atrial fibrillation, inflammation, and statins. Hellenic J Cardiol. 2006;47:51-53.

Tziomalos K. , Athyros VG , Karagiannis A. , et al. Endothelial function, arterial stiffness, and lipid-lowering drugs. Expert Opin Ther Targets. 2007;11:1143-1160.

Kontopoulos AG , Athyros VG , Pehlivanidis AN , et al. Long-term treatment effect of atorvastatin on aortic stiffness in hypercholesterolaemic patients . Curr Med Res Opin. 2003;19:22-27.

Hillege HL , Nitsch D. , Pfeffer MA , et al. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation. 2006;113: 671-678.

Athyros VG , Mikhailidis DP , Papageorgiou AA , et al. The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) study. J Clin Pathol. 2004;57:728-734.

Athyros VG , Mikhailidis DP , Liberopoulos EN , et al. Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study. Nephrol Dial Transplant. 2007;22:118-127.

Tonelli M. , Moyé L. , Sacks FM , et al. Cholesterol and Recurrent Events Trial Investigators: effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. J Am Soc Nephrol . 2003;14:1605-1613.

Collins R. , Armitage J. , Parish S. , et al. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomized placebo-controlled trial Lancet. 2003;361:2005-2016.

Youssef F. , Gupta P. , Seifalian AM , et al. The effect of short-term treatment with simvastatin on renal function in patients with peripheral arterial disease. Angiology . 2004;55:53-62.

Shepherd J. , Kastelein JJ , Bittner V. , et al. Treating to New Targets Investigators: effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study . Clin J Am Soc Nephrol. 2007;2:1131-1139.

Liberopoulos EN , Mikhailidis DP , Athyros VG , et al. The effect of cholesterol-lowering treatment on renal function. Am J Kidney Dis. 2006;47:561.

Tavazzi L. , Tognoni G. , Franzosi MG , et al. Rationale and design of the GISSI heart failure trial: a large trial to assess the effects of n-3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure. Eur J Heart Fail . 2004;6:635-641.